INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 1-5
OCLC –1242424495

International Journal of Medical Science and Public Health Research

Journal Website: https://ijmsphr.com/index.php/ijmsphr

Research Article

HUMAN ERYTHROCYTES AS PRAVASTATIN CARRIERS: A CHARACTERIZATION STUDY

Submission Date: October 22, 2024, **Accepted Date:** October 27, 2024,
Published Date: November 01, 2024

Omar Badawi
Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia

ABSTRACT

The exploration of human erythrocytes (red blood cells) as biocompatible carriers for drug delivery offers promising advancements in targeted therapeutics. This study investigates the feasibility of utilizing erythrocytes as carriers for pravastatin, a commonly used statin for cholesterol management. In vitro methodologies were employed to load pravastatin into erythrocytes, followed by comprehensive characterization of the loading efficiency, encapsulation stability, and release profile. Erythrocyte morphology, membrane integrity, and hemoglobin release were monitored post-loading to assess potential cytotoxic effects. Findings indicate that erythrocytes effectively encapsulate pravastatin with high efficiency, maintain structural stability, and enable a controlled release over an extended period. The results highlight human erythrocytes as a potential drug delivery platform for pravastatin, potentially enhancing its bioavailability and reducing systemic side effects. Further research is needed to optimize loading protocols and confirm in vivo efficacy.

KEYWORDS

Erythrocytes, Red Blood Cells, Pravastatin, Drug Delivery, Encapsulation, Controlled Release, Biocompatibility, Targeted Therapy, In Vitro Study.

INTRODUCTION

Drug delivery systems play a critical role in optimizing therapeutic efficacy while minimizing adverse effects. For lipid-lowering agents like pravastatin, used in managing hypercholesterolemia and reducing cardiovascular risk, efficient and targeted delivery remains a priority to improve patient outcomes and minimize systemic side effects. Pravastatin is a member of the statin class, widely prescribed for cholesterol management due to its effectiveness in lowering LDL cholesterol levels. However,

INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 1-5
OCLC –1242424495

conventional delivery of pravastatin is limited by its systemic distribution, which can lead to undesirable side effects, including muscle pain and liver abnormalities. As such, exploring alternative delivery methods that provide controlled release and reduce off-target distribution has become an area of interest.

Human erythrocytes, or red blood cells, have gained attention as potential carriers for drug delivery due to their biocompatibility, long circulation half-life, and ability to encapsulate various therapeutic agents. Erythrocytes can act as natural drug reservoirs, allowing a slow and controlled release of encapsulated agents over time. This approach has been successful in previous studies with various drugs, showcasing erythrocytes as a promising platform for reducing dosing frequency, enhancing drug stability, and targeting specific

METHOD

This study was designed to investigate the potential of human erythrocytes as carriers for pravastatin, focusing on the loading efficiency, structural integrity, and release profile of the encapsulated drug. Fresh human blood samples were obtained from healthy volunteers with informed consent, and erythrocytes were isolated using standard centrifugation techniques. After centrifugation, plasma and buffy coat were removed to obtain a pure erythrocyte fraction. The erythrocytes were washed multiple times with phosphate-buffered saline (PBS) to ensure removal of plasma proteins and contaminants, maintaining cell integrity and preparing the erythrocytes for drug loading.

To encapsulate pravastatin, a hypotonic dialysis technique was used. Erythrocytes were suspended in a hypotonic solution containing pravastatin, inducing the temporary opening of pores on the erythrocyte membrane and allowing pravastatin to diffuse into the cells. After a set period, the erythrocytes were returned to an isotonic environment, prompting the membrane to reseal with pravastatin trapped inside. The loaded erythrocytes were subsequently washed and resuspended in PBS to remove any unencapsulated pravastatin. Encapsulation efficiency was measured by quantifying the amount of pravastatin within the erythrocytes compared to the total amount introduced.

Characterization of the pravastatin-loaded erythrocytes was carried out to evaluate cell morphology, membrane stability, and hemoglobin release. Microscopic analysis was performed to ensure the loaded erythrocytes maintained typical biconcave morphology, indicating minimal structural disruption. Hemoglobin release was quantified using spectrophotometry to assess membrane stability and potential cytotoxic effects. This step was crucial, as significant hemoglobin release could indicate cell damage, compromising the cells' functionality as drug carriers. Additionally, osmotic fragility tests were conducted to determine the resilience of loaded erythrocytes compared to untreated controls.

To evaluate the release profile, the pravastatin-loaded erythrocytes were suspended in PBS at 37°C and sampled at predefined intervals. At each time point, the sample was centrifuged, and the supernatant was analyzed to measure the amount of pravastatin released. This release study aimed to simulate physiological conditions, assessing whether the erythrocytes could provide a sustained release of pravastatin over time. The cumulative release of pravastatin was calculated and plotted to observe the release kinetics, providing insight into the potential efficacy of erythrocyte-based pravastatin delivery in therapeutic applications.

INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 1-5
OCLC –1242424495

All experiments were performed in triplicate to ensure reliability, and statistical analyses were conducted to compare results from pravastatin-loaded erythrocytes and controls. Data were analyzed using appropriate statistical software, with p-values less than 0.05 considered statistically significant. This methodology provided a comprehensive approach to evaluating the feasibility of using human erythrocytes as carriers for pravastatin, focusing on parameters essential to developing an effective and safe erythrocyte-based drug delivery system.

RESULTS

The study demonstrated successful loading of pravastatin into human erythrocytes, with a high encapsulation efficiency achieved through the hypotonic dialysis method. The encapsulated erythrocytes maintained typical biconcave morphology as observed under microscopic examination, indicating minimal structural alteration post-loading. Hemoglobin release analysis showed that the membrane integrity of loaded erythrocytes was largely preserved, with hemoglobin release values close to those of untreated control erythrocytes, suggesting minimal cytotoxicity or cell lysis. Osmotic fragility tests indicated that the stability of pravastatin-loaded erythrocytes was comparable to that of unmodified erythrocytes, further supporting the structural stability of the cells after encapsulation.

The in vitro release profile of pravastatin from the loaded erythrocytes showed a controlled and sustained release over time. The cumulative release data revealed that a gradual release of pravastatin was achieved over 72 hours, with no significant burst release at the initial stages. This release pattern suggests that erythrocytes can provide a steady release, potentially enhancing the therapeutic duration of pravastatin while minimizing the need for frequent dosing.

DISCUSSION

The results of this study indicate that human erythrocytes have the potential to serve as effective carriers for pravastatin, offering a promising alternative to conventional drug delivery methods. The high encapsulation efficiency achieved with the hypotonic dialysis method highlights the feasibility of loading hydrophilic drugs, such as pravastatin, into erythrocytes. The preservation of erythrocyte morphology and membrane stability post-loading is essential, as these factors are critical to the safety and functionality of the cells as drug carriers. The minimal hemoglobin release observed suggests that pravastatin loading does not significantly compromise erythrocyte integrity, aligning with previous findings that erythrocytes can encapsulate therapeutic agents with minimal cytotoxic effects.

The controlled and sustained release profile observed is particularly significant for pravastatin, as a gradual release aligns well with the pharmacokinetic requirements for maintaining therapeutic plasma concentrations without large fluctuations. This steady release has the potential to enhance pravastatin's efficacy in cholesterol management and may help reduce adverse side effects associated with conventional administration. Additionally, the absence of an initial burst release minimizes the risk of dose dumping, which can lead to sudden high plasma concentrations and related side effects. These properties make erythrocyte carriers an attractive option for extending pravastatin's therapeutic duration, potentially improving patient compliance and treatment outcomes.

INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 1-5
OCLC –1242424495

While this in vitro study provides valuable insights, further research is required to confirm these findings in vivo. Studies examining the pharmacokinetics, biodistribution, and long-term safety of pravastatin-loaded erythrocytes in animal models are necessary before clinical application. Additionally, optimization of the loading protocol and encapsulation techniques may further enhance drug retention and release characteristics, maximizing therapeutic potential.

CONCLUSION

This study demonstrates that human erythrocytes are promising carriers for pravastatin, with high encapsulation efficiency, preserved membrane integrity, and a controlled release profile. The results support the feasibility of using erythrocyte-based delivery systems to provide sustained and targeted pravastatin release, potentially enhancing its therapeutic efficacy and safety profile. Future studies are required to confirm these findings in vivo and further refine the encapsulation process. This approach opens avenues for erythrocyte-mediated drug delivery of pravastatin and other therapeutic agents, marking a step forward in the development of biocompatible and effective drug delivery systems.

REFERENCE

1. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002; 87(4):1451-1458.
2. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Life Sciences. 1999;65(13):1329-1337.
3. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002; 41(5):343-370.
4. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39:397–412.
5. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2004; 57(2):181-187.
6. Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, Kobayashi S. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sciences. 2006; 78(24):2852-2859.
7. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006; 151(2):273 - 281.
8. Oda S, Nagahama R, Nakano K, Matoba T, Kubo M, Sunagawa K, Tominaga R, Egashira K. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. JVS. 2010;52(2):412-420.
9. Kang B. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm. 2004; 274(1-2):65-73.
10. Charman WN, Chan HK, Finnin BC, Charman SA. Drug Delivery: A Key Factor in Realising the Full Therapeutic Potential of Drugs. Drug Dev Res. 1999;46:316-327.
11. Margulis-Goshen K, Magdassi S. Formation of simvastatin nanoparticles from microemulsion. Nanomedicine: NBM. 2009; 5(3):274-281.
12. Gupta A, Mishra AK, Bansal P, Kumar S, Gupta V, Singh R, Kalyan GS. Cell Based Drug Delivery

INTERNATIONAL JOURNAL OF MEDICAL SCIENCE AND PUBLIC HEALTH RESEARCH (ISSN – 2767-3774)
VOLUME 05 ISSUE 11 Pages: 1-5
OCLC –1242424495

System Through Resealed Erythrocyte- A Review. Int J Pharm. 2010; 2(1):23-30.

13. Shavi GV, Doijad RC, Deshpande PB, Manvi FV, Meka SR, Udupa N, Omprakash R, Dhirendra K. Erythrocytes as carrier for prednisolone: in vitro and in vivo evaluation. Pak J Pharm Sci. 2010; 23(2):194-200.
14. Gothoskar AV. Resealed Erythrocytes:A Review. J Pharm Technol. 2004;:140-158.